Resistance to novel drug classes
Open Access
- 1 November 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in HIV and AIDS
- Vol. 4 (6), 531-537
- https://doi.org/10.1097/coh.0b013e328331d4b1
Abstract
Understanding the mechanisms that underlie resistance\ud development to novel drugs is essential to a better clinical management of\ud resistant viruses and to prevent further resistance development and spread.\ud RECENT FINDINGS: Integrase inhibitors and CCR5 antagonists are the more recent\ud antiretroviral classes developed. The HIV-1 integrase, responsible for the\ud chromosomal integration of the newly synthesized double-stranded viral DNA into\ud the host genomic DNA, represents a new and important target; and two integrase\ud inhibitors (INIs), raltegravir and elvitegravir, have been shown promising\ud results in clinical trials. Viral entry is also an attractive step for the\ud development of new drugs against HIV variants resistant to current antiretroviral\ud drugs, and two CCR5 antagonists have been designed to inhibit HIV-1 binding to R5\ud co-receptor and are under clinical investigation.\ud SUMMARY: Drug resistance to INIs occurs through the selection of mutations within\ud HIV integrase. The kinetic of selection seems rapid and one mutation alone is\ud able to confer resistance to integrase inhibitor, suggesting that this class of\ud drug has a low genetic barrier. Two ways could explain the failure of the CCR5\ud antagonist class: a rapid outgrowth of pre-existing archived X4 virus or the\ud selection of a resistance to CCR5 antagonists through amino acid changes in VKeywords
This publication has 65 references indexed in Scilit:
- Analysis of Natural Sequence Variation and Covariation in Human Immunodeficiency Virus Type 1 IntegraseJournal of Virology, 2008
- In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected SubjectJournal of Virology, 2008
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studiesThe Lancet, 2008
- The Challenge of HIV-1 Subtype DiversityNew England Journal of Medicine, 2008
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In VitroAntimicrobial Agents and Chemotherapy, 2008
- Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)Journal of Virology, 2008
- Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside InhibitorsJournal of Virology, 2007
- The role of lysine 186 in HIV-1 integrase multimerizationVirology, 2007
- High Prevalence of the K65R Mutation in Human Immunodeficiency Virus Type 1 Subtype C Isolates from Infected Patients in Botswana Treated with Didanosine-Based RegimensAntimicrobial Agents and Chemotherapy, 2006
- Genotypic predictors of human immunodeficiency virus type 1 drug resistanceProceedings of the National Academy of Sciences of the United States of America, 2006